{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Marquez-Palencia M"],"funding":["American Cancer Society","National Science Foundation Graduate Research Fellowship Program","NCI NIH HHS","Welch Foundation","METAvivor","Cancer Prevention and Research Institute of Texas"],"pagination":["675-687"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11221606"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["84(5)"],"pubmed_abstract":["Therapy resistance and metastatic progression are primary causes of cancer-related mortality. Disseminated tumor cells possess adaptive traits that enable them to reprogram their metabolism, maintain stemness, and resist cell death, facilitating their persistence to drive recurrence. The survival of disseminated tumor cells also depends on their ability to modulate replication stress in response to therapy while colonizing inhospitable microenvironments. In this study, we discovered that the nuclear translocation of AXL, a TAM receptor tyrosine kinase, and its interaction with WRNIP1, a DNA replication stress response factor, promotes the survival of HER2+ breast cancer cells that are resistant to HER2-targeted therapy and metastasize to the brain. In preclinical models, knocking down or p"],"journal":["Cancer research"],"pubmed_title":["AXL/WRNIP1 Mediates Replication Stress Response and Promotes Therapy Resistance and Metachronous Metastasis in HER2+ Breast Cancer."],"pmcid":["PMC11221606"],"funding_grant_id":["RR170003","GAA202106-0027","RSG-20-47-01-CSM","2019281049","P50 CA098131","I-2087-20210327","P30 CA142543"],"pubmed_authors":["Peng Y","Davis AJ","Parida PK","Brekken RA","Gonzalez-Ericsson PI","Aguilera TA","Hanker AB","Kim K","Diegeler S","Arteaga CL","Lorens JB","Mobley BC","Ghosh S","Sanders ME","Whitehurst AW","Reza Herrera L","Lewis CM","Marquez-Palencia M","Das NM","Malladi S"],"additional_accession":[]},"is_claimable":false,"name":"AXL/WRNIP1 Mediates Replication Stress Response and Promotes Therapy Resistance and Metachronous Metastasis in HER2+ Breast Cancer.","description":"Therapy resistance and metastatic progression are primary causes of cancer-related mortality. Disseminated tumor cells possess adaptive traits that enable them to reprogram their metabolism, maintain stemness, and resist cell death, facilitating their persistence to drive recurrence. The survival of disseminated tumor cells also depends on their ability to modulate replication stress in response to therapy while colonizing inhospitable microenvironments. In this study, we discovered that the nuclear translocation of AXL, a TAM receptor tyrosine kinase, and its interaction with WRNIP1, a DNA replication stress response factor, promotes the survival of HER2+ breast cancer cells that are resistant to HER2-targeted therapy and metastasize to the brain. In preclinical models, knocking down or p","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2026-06-02T03:49:28.252Z","creation":"2025-04-06T10:48:11.181Z"},"accession":"S-EPMC11221606","cross_references":{"pubmed":["38190717"],"doi":["10.1158/0008-5472.can-23-1459","10.1158/0008-5472.CAN-23-1459"]}}